Health CanadaGeneral Alert
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairme...
Published: January 17, 2022Recall ID: 63819Category: generalCountry: Canada
Reason for Recall / Hazard
Labelling - New safety information - Supply - COVID
Product Description & Identification
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
Affected Products
PAXLOVID (150 mg nirmatrelvir; 100 mg ritonavir)
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63819 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/paxlovid-nirmatrelvir-and-ritonavir-dosing-and-dispensing-renal-impairment-risk |
| Issue | Labelling - New safety information - Supply - COVID |
| Title | PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels |
| Product | PAXLOVID (150 mg nirmatrelvir; 100 mg ritonavir) |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-01-17 |
| Organization | Marketed health products |